Mirabella Financial Services LLP Makes New $2.45 Million Investment in STERIS plc $STE

Mirabella Financial Services LLP acquired a new stake in shares of STERIS plc (NYSE:STE) in the third quarter, according to its most recent disclosure with the SEC. The firm acquired 9,907 shares of the medical equipment provider’s stock, valued at approximately $2,447,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Steigerwald Gordon & Koch Inc. purchased a new position in shares of STERIS in the third quarter worth $25,000. Cloud Capital Management LLC purchased a new position in STERIS during the third quarter valued at $29,000. Geneos Wealth Management Inc. grew its stake in STERIS by 416.0% during the first quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 104 shares in the last quarter. TruNorth Capital Management LLC bought a new stake in STERIS in the 3rd quarter valued at $37,000. Finally, Root Financial Partners LLC purchased a new stake in STERIS in the 3rd quarter worth $39,000. Institutional investors own 94.69% of the company’s stock.

Insider Activity at STERIS

In related news, Director Cynthia L. Feldmann sold 3,098 shares of the stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $237.21, for a total value of $734,876.58. Following the completion of the transaction, the director owned 705 shares of the company’s stock, valued at approximately $167,233.05. This trade represents a 81.46% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.07% of the company’s stock.

STERIS Trading Down 1.8%

STE stock opened at $216.25 on Thursday. The firm has a fifty day moving average price of $248.56 and a 200 day moving average price of $249.93. STERIS plc has a fifty-two week low of $204.90 and a fifty-two week high of $269.44. The firm has a market cap of $21.21 billion, a PE ratio of 30.16 and a beta of 1.05. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.75 and a current ratio of 2.48.

STERIS (NYSE:STE) last released its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $2.53 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $2.53. STERIS had a net margin of 12.15% and a return on equity of 14.34%. During the same quarter in the prior year, the business earned $2.32 EPS. The company’s revenue was up 9.2% compared to the same quarter last year. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. Sell-side analysts anticipate that STERIS plc will post 9.08 earnings per share for the current fiscal year.

STERIS Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 19th. Stockholders of record on Tuesday, February 17th will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 1.2%. The ex-dividend date is Tuesday, February 17th. STERIS’s dividend payout ratio is currently 35.15%.

Analyst Upgrades and Downgrades

STE has been the subject of several research reports. Wall Street Zen raised shares of STERIS from a “buy” rating to a “strong-buy” rating in a report on Saturday, March 7th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of STERIS in a report on Friday, January 9th. Six analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, STERIS has an average rating of “Moderate Buy” and an average price target of $275.20.

STERIS Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.